Bridging the gap


Intravacc develops innovative platforms and methods to improve the effectiveness, stability and safety of vaccines.

Read More Close

Intravacc is continuously investing in R&D platforms to facilitate vaccine development. Early development includes vaccine strain design to generate bacterial, viral and cellular seeds for efficient vaccine production.

We also carry out studies on adjuvants and delivery systems, resulting in safe products that are efficacious.

Our successful R&D efforts are then further developed into services we offer to clients.

To investigate the efficacy of vaccines, Intravacc performs immunological research to unravel the mechanisms of action of vaccine concepts. These immunological assays are used during preclinical and clinical stages.    


Our expertise includes

  • Immunology
  • Molecular biology
  • Animal models
  • Systems vaccinology
  • Adjuvants
  • Vaccine delivery





Want to know more? Contact us at


Process Development

Process Development

Intravacc develops bacterial and viral vaccines from discovery to phase II clinical trials. We use our own advanced technologies, such as Vero cell line and the OMV platform.

Read More Close

We can apply our long-standing and extensive experience in vaccine development to design rational and modelled processes together with our clients.

Using mathematical models we can safely scale from lab to commercial scale bioreactors.


Viral vaccine R&D

Focusing on the treatment or prevention of viral diseases such as Polio, Respiratory Syncytial Virus, Enterovirus, Influenza, Rabies and Rotavirus. We have access to a qualified Vero cell line and specialized equipment to perform research for WHO, the Dutch Ministry of Health and collaborate with other parties.


Bacterial Vaccine R&D

Focusing on Conjugate vaccine technology (for vaccines for Hib and Shigella) and Outer Membrane Vescicles (OMV) technology (Pertussis, Meningococcal B, Lyme disease and Tuberculosis research)



Main features

  • Established cGMP Vero cell line
  • Technology platform suitable for highly purified inactivated and live-attenuated vaccines
  • OMV-based vaccine technology platform suitable for heterologous antigen expression
  • State-of-the-art production technologies (including single-use and re-usable equipment)
  • Highly qualified BSL-2 and GxP trained personnel
  • Experience in Design of Experiments (DoE), and multiparametric data analysis
  • High-throughput methods for both Up-stream and Down-stream processing
  • Animal Component Free and Chemically Defined processing as standard methods
  • Tested processes to assure process robustness and reproducibility
  • Full panel of analytical capabilities for in-process controls
  • Scalable processes from 2 mL to pilot-scale and commercial manufacturing scale
  • Experience in Technology Transfer of vaccine production processes
  • CMC consulting capacities


Check out our factsheets:

Hand Foot Mouth Disease




OMV Pertussis


Sabin IPV

Vero cells


Want to know more? Contact us at:



Intravacc offers assay development and vaccine characterization services. We specialise in immunoassays, molecular biology methods, physicochemical analyses, and biological assays.

Read More Close

Assays to prove the quality of a new vaccine

The quality is a decisive factor in the development of new vaccines. Intravacc uses multiple instructive assays and innovative techniques to guarantee the quality of intermediates and finished product. Our tests focus on the composition, concentration, efficacy, purity, safety, stability and identity of the new vaccine candidate.



  • ELISA (direct and capture assays for antibody titres in sera and antigen concentrations in vaccine formulations)
  • Multiplex Immunoassay (cytokines, antibody titres against multiple antigens, antigen concentrations in combination vaccines)
  • Biosensor analysis (epitope integrity, epitope mapping, affinity measurements, calibration free concentration analysis)
  • Immunoproteomics (identification of immunogenic proteins, B-cell epitopes and naturally processed T-cell epitopes by mass spectrometry)


Molecular biology methods

  • qPCR (quantification of viruses and bacteria by real time Polymerase Chain Reaction)
  • Deep sequencing (identity, sequence and genetic changes of viruses)


Physicochemical analyses

  • Mass spectrometry (identity, quantity, purity and chemical modifications of antigens, host cell proteins)
  • 2-D electrophoresis (antigen composition )
  • Fluorescence spectroscopy (conformation and aggregation of antigens)
  • Circular dichroism (secondary and tertiary structure of antigens)
  • Differential scanning calorimetry (denaturation temperature of antigens)
  • particle analysis by Dynamic Light Scattering (DLS), Field Flow Fractionation - Multiangle Laser Light Scattering (FFF-MALLS) 


Analytical techniques

  • HPLC (amino acid determination, residual phenol, monosaccharides, oligosaccharides, excipients)
  • GC (LPS analysis, phospholipids)
  • NMR (medium composition, metabolite analysis, chemical composition, impurities, excipients)


Biological assays

  • CCID50 (active virus titre)
  • Vero cell assay (residual toxin activity)


Want to know more? Contact us at:

Animal models

Animal models

Intravacc is one of the leading players in global 3R research (reduce, replace and refine animal experiments).

Read More Close

We have developed several new methods, some of which were accepted by the European Pharmacopoeia.

In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in an IMI-funded European consortium on consistency testing.


Research focus:

  • Cell-based in vitro models, pysico-chemical techniques and immunochemical assays
  • Development of in-vitro assays
  • Transgenic mouse model for neurovirulence testing of OPV or Sabin-IPV lots


Achievements include:

  • Vero cell tests replacing the specific toxicity test in guinea pigs (diphtheria vaccine)
  • Serological tests replacing challenge procedures in potency testing (diphtheria and tetanus vaccine)
  • The use of human endpoints replacing lethal/severe clinical endpoints 


Check out our factsheet on our 3R research


Want to know more? Contact us at:

Pilot-scale production

Pilot-scale production

Intravacc is home to a GMP facility for production of vaccines on pilot scale. This includes a state-of-the-art 100 m2 C/BSL-2 cleanroom.

Read More Close

Intravacc has years of experience in producing GMP batches for phase I and II clinical studies of viral and bacterial vaccines.

We have all the required equipment at our disposal for Upstream and Downstream Processing, including bioreactors of up to 100 liter.

This means we can offer a complete CTM production trajectory from seed lot production till released clinical batches.



  • Fully adaptable cleanrooms
  • 100m2 class C/BSL-2 cleanroom for active processes
  • 25m2 class C cleanroom for inactive processes
  • Dedicated cleaning & sterilization department


Want to know more? Contact us at:

Clinical & Regulatory

Clinical & Regulatory

Our inhouse clinical and regulatory scientists form part of each project team that develops a new vaccine. They offer regulatory support right from the start.

Read More Close

Innovative vaccines are mostly complex products for which there is often no clear regulatory guidance available. That is why our Regulatory and Clinical Affairs (RCA) team is involved in the development of these products right from the start.

By taking into consideration the regulatory restraints and requirements in an early phase of development, a lean transition to the next phase towards a marketed product can be made. 

Our team provides regulatory support in vaccine development projects through early involvement, assessment of potential regulatory requirements, preparation of risk assessments and by seeking informal or formal scientific advice with national competent authorities.

Support varies from the preparation of pharmaceutical, preclinical, and clinical development plans and reports, to the submission of relevant regulatory dossiers (IMPD/IND, CTA) to health authorities.


CMC activities

  • Raw materials assessment
  • Quality Target Product Profile-design, define product specifications
  • Gap analyses and risk assessments (e.g. Viral safety/TSE/Impurities/GMOs)
  • Design of program for stability testing
  • Comparability studies


  • Pre-clinical evaluation of vaccine immunogenicity, efficacy
  • Coordination of non-clinical toxicology and safety studies
  • Non-clinical development plan


  • Product Profile design
  • Clinical Development Pathway advise
  • Clinical study design
  • CRO selection and management


Want to know more? Contact us at:

Co-Development with partners

Co-Development with partners

We are always open to work closely together with academia, public health organizations (WHO, BMGF), and biotech and pharmaceutical companies. This way, we benefit from each other's strengths in developing and innovating vaccines.

Read More Close

Are you looking for an experienced partner who can take your discovery to the next level of preclinical research?

Are you looking for a partner with GMP facilities, who can produce clinical lot material for your toxicity studies and phase I/II clinical trials?

Are you looking for a partner with a patent portfolio covering a variety of vaccine leads, novel vaccine technologies and adjuvants?

We are happy to discuss these and other possibilities for collaboration and co-development.


Vaccine concepts/technologies available for licensing

  • RSV
  • EV71
  • Pertussis
  • Alzheimer
  • LPS-mutants
  • Vero cells
  • MenB
  • Hib-conjugate vaccine


Want to know more? Contact us at

About Intravacc

Intravacc is an experienced R&D organization with a proven track record in vaccinology of over 100 years. We have a wide range of expertise to independently develop vaccines from lead concept to clinical phase I/II studies as wel as our own product pipeline and patents.     

Read More Close
  • a wide range of science-based, one-stop-shop solutions
  • state-of-the-art facilities on site
  • Bacterial and Viral vaccines
  • OMV technology
  • Vero cell platforms
  • Innovative vaccine design
  • 3R research

Check out our factsheet on Intravacc 

Want to know more? Contact us at:






FActsheet vaccine



Intravacc announces the establishment of ‘Intravacc B.V.’, preparing for its privatization

News | 01-02-2019

Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.

In May 2018, the Dutch Ministry of Health, Welfare and Sport announced the start of the privatization process of the activities of Intravacc a leading organisation in the field of vaccines research & development. As the privatization is progressing, the buyer of Intravacc is expected to be announced in the second quarter of 2019.

Preparing for the privatization, Intravacc B.V., a private company with limited liability, was established today. Once the shares of Intravacc are sold to the selected buyer, Intravacc B.V. will become operational and all assets, staff, intellectual property and contracts & agreements will be transferred to the new entity. This ensures a smooth transition of the business and the knowledge base of Intravacc with no interruption in servicing current customers.

Intravacc and CDBIO sign a research and license agreement to further develop and commercialize a Meningococcal B vaccine

News | 28-12-2018

Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.

Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.

Intravacc’s unique Nonamen® technology offers a broad panel of PorA proteins inserted in so called Outer membrane vesicles (OMV) expected to induce protection against the Meningococcal B (MenB) disease. Furthermore, the Nonamen® technology can be included in a Meningitis combination vaccine.

Under the agreement, both parties will collaborate to establish the development of an efficacious vaccine against prevalent Men B serotypes in China.

“We are very happy to partner with CDBIO and to be able to expand the global reach of our Nonamen technology. We trust this will help to prevent the occurrence of Men B in China considerably”, said Mr Nico Oudendijk, General Director of Intravacc.


Intravacc and BCHT enter into license agreement for production of a Hib conjugate vaccine

News | 12-11-2018

Intravacc and BCHT have entered into a non-exclusive license agreement for the development of a Hib conjugate vaccine within the People’s Republic of China.

Intravacc and Changchun BCHT Biotechnology Co today announced that they have entered into a non-exclusive license agreement towards the development ofa Haemophilus influenzae Type B (Hib) Conjugate Vaccine within the People’s Republic of China. By combining their strengths, the two parties can together lower the incidence of this vaccine preventable disease in China.

Through this agreement, BCHT obtained Intravacc’s unique Hib conjugate technology to further develop, produce and sell the vaccine. The vaccine consists of a Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled to tetanus toxoid that has shown to be effective in preventing the disease. The Intravacc Hib vaccine technology has already been used for the vaccination of 100s of millions of children.The license agreement between Intravacc and BCHT will now help to reduce the incidence of Hib in Chinese children.

Of the 6 types of H influenzae, type B is responsible for more than 90% of systemic infections. Hib can cause serious illness like acute lower respiratory tract infection and bacterial meningitis. In China, for children under age of 5 years old, the incidence of meningitis caused by Hib was reported in a survey about 10.7/100 000 annually; 9.7% of these cases were fatal, and 21.4% of survivors suffered from neurological or psychological problems. The agreement between Intravacc and BCHT will help to bring this number down considerably.

‘’It’s great to hear that the innovative work of our researchers at Intravacc will contribute to the prevention of Hib in China. We are proud to partner with BCHT to prevent this disease.” said Mr Nico Oudendijk, General Director of Intravacc.

Intravacc and TherapyX partner to develop world’s first prophylactic vaccine against Gonorrhea

News | 15-10-2018

Intravacc has entered into a strategic partnership with TherapyX for the co-development of the world’s first prophylactic vaccine to provide lasting, protective immunity against Neisseria gonorrhoeae.

Intravacc is pleased to announce that it has entered into a strategic partnership with TherapyX for the co-development of NGoXIMTM, the world’s first prophylactic vaccine against infection with Neisseria gonorrhoeae. This new vaccine is intended to enhance specific adaptive immune responses that provide lasting, protective immunity against N. gonorrhoeae. NGoXIMTM is a combination of a sustained-release formulation of interleukin 12 (GneX12TM) and bacterial outer membrane vesicles (OMV) formulated for mucosal delivery.

No effective gonorrhea vaccine is currently available and the disease is known to be acquired repeatedly with apparently no development of protective immunity from previous infection. The American Centers for Disease Control and Prevention (CDC) has listed antibiotic-resistant N. gonorrhoeae as one of the top three pathogens presenting “an immediate public health threat that requires urgent and aggressive action.” A recent WHO technical consultation on vaccines against sexually transmitted infections (2017) called for renewed efforts to develop a vaccine against gonorrhea. This partnership effort is a direct response to that call.

Under the terms of the partnership agreement, TherapyX will focus efforts on IND-enabling efficacy and toxicology studies in primates while Intravacc will be responsible for the discovery and development of OMVs with improved immunogenic properties and reduced toxicity. Financial terms were not disclosed.

“We are thrilled to partner with Intravacc” said Dr. Dominick L. Auci, Vice President for Research and Development at TherapyX. “They bring over 100 years of expertise in vaccines including novel OMV technology to this important project. We couldn’t be working with a more experienced, innovative and dedicated team”.

“We are delighted to be working with TherapyX” said Mr. Nico Oudendijk, General Director of Intravacc. “The IL-12 technology they bring into the project is key to develop an efficacious vaccine against this disease.”


Serum Institute of India and Intravacc to develop Bioneedles

News | 04-06-2018


New Delhi/Bilthoven, 29th May 2018: Life Sciences and Healthcare is a vital area of collaboration for India and the Netherlands.  Growing market opportunities in India, combined with the Netherlands’ strengths in Healthcare, create excellent opportunities for Indo-Dutch partnerships that address shared societal challenges with smart solutions. One of the key healthcare challenges that are being turned into Indo-Dutch collaborative solutions is vaccine delivery.

Serum Institute of India and Intravacc (part of the Netherlands Ministry of Health, Welfare and Sports) will jointly develop a novel delivery system for vaccines: Bioneedles. The Bioneedle, a tiny biodegradable mini implant, is a unique approach with ground breaking potential to transform vaccination campaigns, especially in low and middle income countries. The parties will develop Bioneedles for vaccines against measles and rubella. The Memorandum of Understanding confirming their collaboration was signed in the presence of Mark Rutte, Prime Minister of the Netherlands, Sigrid Kaag, Dutch Minister for Foreign Trade and Development Cooperation, Bruno Bruins, Dutch Minister for Medical Care and Sports, Hans de Boer, CEO, Confederation of Netherlands Industry and Employers VNO-NCW, and H.E Alphonsus Stoelinga, Ambassador of the Netherlands to India, during the Netherlands Trade Mission to India last week. The signatories were Dr Suresh Jadhav, Executive Director, Serum Institute of India and Thijs Veerman, CEO, Intravacc.

“I am happy that this MoU was signed during The Netherlands Trade mission to India. The collaboration between SII and Intravacc is a good example of a cooperation in which companies from India and The Netherlands join forces to help improve health worldwide,” Bruno Bruins, Minister for Medical Care of The Netherlands was quoted as saying. 


Currently, vaccines are mostly administered through intramuscular or subcutaneous injection by needle and syringe. The use of needles however may cause pain and fear in vaccinated people, and  requires trained personnel, which is not always readily available in low and middle income countries.  Moreover, needle waste can be hazardous due to reuse and needle-stick injuries and, as a result, transmission of infectious diseases like hepatitis or HIV. To overcome these issues, numerous alternative vaccine administration devices and methods are currently being developed.

One of the most promising technologies in alternative vaccine delivery is a Bioneedle-based delivery device. “Vaccines play a critical role in public health globally- and for Intravacc, India is a vital market for partnerships in vaccine development. This project could potentially mark a major step towards vastly improved access to vaccines especially in low and middle income countries. We are very happy to be involved in such an innovative project with our Indian partner,” Thijs Veerman, CEO, Intravacc says.

Bioneedles are composed of a starch-like polymer, a product that is naturally degraded by the human body. The Bioneedle is administered by an implantation under the skin with an applicator. The Bioneedle matrix will degrade after implantation, which enables the release of the freeze dried vaccine. This reduces hazardous needle waste and results in a quick and pain-free delivery of the vaccine; it may even abolish the need for trained professionals to perform vaccinations – a huge benefit in developing countries where trained medical personnel is scarce. In addition, vaccines in Bioneedles are both freeze and heat stable and can be stored, transported and distributed outside any cold chain. Preclinical concepts of Bioneedles have been established with numerous vaccines, including tetanus, polio, influenza and hepatitis B. In all cases, Bioneedles filled with vaccine were able to induce potent systemic humoral immune responses against the respective antigen. Serum Institute of India and Intravacc will jointly develop Bioneedles for vaccines against Measles and Rubella. Intravacc will optimize the formulation of the vaccine and preparation of the Bioneedles and freeze drying process; Serum Institute of India will supply the MR vaccine. Both parties will search for a partner, preferably from India, for developing a suitable applicator device to administer the Bioneedles.

“We are now the world's largest vaccine manufacturer by number of doses produced. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute, saving millions of lives throughout the world,” says Dr Suresh Jadhav, Executive Director, Serum Institute of India. With this project we continue to build a sustainable, long-term partnership with Intravacc in our effort to manufacture affordable life-saving vaccines .”

All together this is a unique approach with ground breaking potential to transform vaccination campaigns, especially in the low and middle income countries.

Dutch Ministry of Health announces privatization of Intravacc

News | 14-05-2018

The Dutch Ministry of Health, Welfare and Sport has announced the start of the privatization process of the activities of Intravacc. Collegium Advisors is to act as lead advisor and co-ordinator of the privatization process.

Bilthoven, May 8th, 2018 - The Dutch Ministry of Health, Welfare and Sport (Ministerie van Volkgezondheid, Welzijn en Sport or MoH) has announced the start of the privatization process of the activities of Intravacc.

Intravacc (Institute for Translational Vaccinology) has a wide range of relevant expertise in independently developing vaccines from lead concept to clinical phase I/II studies, and has its own product pipeline and patents. Moreover, it provides and contracts R&D services to a range of public and private customers. During the last several decades, Intravacc has positioned itself as a global leader in the development of vaccines aiding in the eradication of Polio and has engaged in the research and development of bacterial and viral vaccines against, amongst others, Respiratory Syncytial Virus (RSV), Shigella, Rotavirus, Hib and DTP.

Intravacc was originally formed to perform public tasks concerning research and development of new vaccines resulting from the ambitions and objectives set out by the Dutch State. The company’s aim is to develop safe, effective and affordable vaccine concepts in order to find sustainable solutions to improve public health worldwide. Intravacc is located in Bilthoven, the Netherlands, where it operates state-of-the-art R&D and Good Manufacturing Practice (GMP) facilities for conducting vaccine research.

As a result of the increasing commercial focus of the organization and its close collaboration with the (global) pharmaceutical industry and Global Health parties such as the World Health Organization and the Bill and Melinda Gates Foundation, MoH decided Intravacc would be better suited in a private setting. In June 2015, the Minster of MoH informed the Dutch House of Representatives on its intent to privatize Intravacc and, has now obtained all required political approval to commence the privatization process in order to secure a suitable prospective buyer.

Collegium Corporate Finance and Valuation Advisors has been appointed to act as lead advisor to the MoH during the privatization of Intravacc. Collegium will aim to inform potential prospective buyers about the timelines and structure of the privatization process. Any contact and all expressions of interest with regards to the privatization process should be expressed via Collegium (

Contact details: Collegium Corporate Finance and Valuation Advisors,
Joachim Schulz, Managing Director, Tel: +31-10 203 7856.
Correspondence address: Westplein 11, 3016 BM Rotterdam, The Netherlands.



Would you like to join our team?


Managementassistent m/v (INT108)

Close Binnen Intravacc zijn wij nogmaals op zoek naar een geschikte

Managementassistent m/v (INT108)

Het Instituut voor Translationele Vaccinologie (Intravacc) is dé plek in Nederland met een breed toegankelijke en complete infrastructuur voor translationele vaccinonderzoek en -ontwikkeling. Op het instituut worden goede ideeën uit de wetenschap verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Het instituut rekent zowel de (inter)nationale overheden als diverse farmaceutische en biotech bedrijven tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd tot een publiek-private onderneming.


Binnen Intravacc zijn we op zoek naar een geschikte

Managementassistent m/v

(32 - 36 uur per week)

Vacaturenummer: INT108



In de functie van Managementassistent ben je primair verantwoordelijk voor de secretariële ondersteuning van het managementteam (MT) van Intravacc. De organisatie is volop in ontwikkeling door de verzelfstandiging, waardoor er in sommige gevallen snel geanticipeerd moet worden.

Je zorgt dat de MT-leden hun werk goed kunnen uitvoeren, zonder zich druk te hoeven maken over randzaken. Je ondersteunt en adviseert het MT gevraagd en ongevraagd op tactisch en operationeel niveau. Je begrijpt waar de prioriteiten van het MT liggen en beheert en bewaakt op basis daarvan de druk bezette agenda's.

Je bereidt de agenda van het MT-overleg voor, beoordeelt aangeleverde stukken op helderheid en compleetheid en notuleert de vergadering. Daarnaast faciliteer je de communicatie met de interne organisatie over de genomen MT-besluiten. Ook verricht je algemene secretariële en administratieve werkzaamheden, zoals het boeken van reizen en het aanvragen van visa.

Kortom: jij bent degene die onze MT-leden ontzorgt!

Tevens ben je het aanspreekpunt voor de medewerkers van Intravacc en zorg je voor informatieverstrekking, organisatorische werkzaamheden en facilitaire dienstverlening. Hierbij wordt voornamelijk gewerkt met Outlook, SAP, Skype voor Business en Sharepoint. Samen met een collega vorm je het secretariaat van Intravacc.



  • Afgeronde (bij voorkeur secretariële) HBO opleiding;
  • Minimaal 5 jaar relevante werkervaring, waarbij onze voorkeur uitgaat naar werkervaring binnen zowel de overheid als het bedrijfsleven;
  • Ruime ervaring met notuleren;
  • Uitstekende kennis van de Nederlandse en de Engelse taal in woord en geschrift;
  • Je kunt snel schakelen, inspelen op ad hoc zaken en je bent gewend in een hoog tempo te werken;
  • Je bent initiatiefrijk en kunt zowel zelfstandig als goed in teamverband werken;
  • Je bent integer, professioneel en open;
  • Je hebt gevorderde kennis van kantoorapplicaties en –programma’s (Outlook, Excel, Word, Power Point);
  • Kennis van SAP, Skype voor Business en Sharepoint is een pré



Competenties die wij belangrijk vinden bij onze nieuwe collega

proactief, accuraat, vooruitdenkend, stressbestendig, organisatorisch sterk, klantgericht, ondernemend en nauwkeurig.



Het salaris is, afhankelijk van opleiding en ervaring, maximaal € 3.452,47 bruto per maand (BBRA-schaal 8). Het salaris is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering. Je wordt aangesteld als Managementondersteuner volgens de indeling in het Functiegebouw Rijk.

Het betreft een tijdelijke aanstelling voor de duur van 1 jaar. Bij gebleken geschiktheid zal de tijdelijke aanstelling worden omgezet in een aanstelling voor onbepaalde tijd.



Voor meer informatie over de functie kun je terecht bij Daniëlle Lankveld, Chief Operational Officer, 030-7920476.



Je sollicitatie kun je sturen naar tot en met donderdag 21 november 2019.


Let op VWNW en interne kandidaten genieten de voorkeur.


Download de vacaturetekst (pdf)


Acquisitie n.a.v. deze vacature wordt niet op prijs gesteld


Wetenschappelijk medewerker assay development (INT119)

Close Binnen Intravacc zoeken we voor de afdeling ADF een

Wetenschappelijk medewerker assay development (INT119)

Intravacc is een toegepast wetenschappelijk onderzoekinstituut dat onderzoek doet naar nieuwe vaccins. Door Intravacc worden enerzijds veelbelovende ideeën uit de wetenschap beschermd en verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Anderzijds wordt door Intravacc de beschikbare kennis op het gebied van vaccinontwikkeling en -productie ingezet om R&D opdrachten voor klanten uit te voeren. Het instituut rekent zowel de (inter)nationale overheid als bedrijven, onder andere binnen de innovatieve farmaceutische industrie, tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd, dus volop in beweging.

Binnen Intravacc zoeken we voor de afdeling ADF een

Wetenschappelijk medewerker assay development

36 uur per week

vacaturenummer INT119



De afdeling Analysis, Delivery & Formulation (ADF) werkt aan opzetten van biofysische en immunochemische methoden om vaccins te karakteriseren.



Je zult als wetenschappelijk medewerker assay development verantwoordelijk zijn voor het ontwerpen en opzetten van analysemethoden voor vaccins. Jouw kennis en expertise van biofysische en immunochemische technieken zul je gebruiken om testen te ontwikkelen die de kwaliteit van vaccins kunnen vaststellen, zodat een maximale veiligheid en werkzaamheid gegarandeerd kan worden.


De afdeling Analysis, Delivery & Formulation (ADF) beschikt over diverse laboratoria geschikt voor het opzetten en uitvoeren van analyses van vaccins.



  • Wetenschappelijke ondersteuning geven aan projecten en de afdeling op het gebied van biofysische en immunochemische methoden voor karakteriseren van vaccins
  • Expertise uitbouwen op het gebied van het karakteriseren van vaccins
  • Ontwikkelen van ontwikkeling van formuleringen en test de producten d.m.v. stabiliteitsstudies
  • Collega’s ondersteunen en begeleiden bij de uitvoer en de ontwikkeling van biofysische en immunochemische analysemethoden voor vaccins
  • Onderzoeksplannen, rapporten, manuscripten en technische documenten schrijven en beoordelen
  • De afdeling adviseren op het gebied van ontwikkeling van biofysische en immunochemische analyses
  • Bijdragen aan het goed functioneren van de onderzoekslaboratoria
  • De implementatie van nieuwe analysemethoden begeleiden voor de kwaliteitscontrole van de (nieuwe) vaccins 




  • Relevante universitaire opleiding (PhD) in de richting van farmacie, biologie, biochemie of chemie
  • Onderzoekservaring van minimaal 4 jaar op het gebied van karakteriseren van biopharmaceuticals
  • Ervaring met fysisch-chemische en immunochemische technieken (bijv. DSC, DLS, FFF-MALS, HPLC, IEF, electroforese, ELISA, biosensor analyse, TCID50)
  • Ervaring met het opzetten van analytische methoden voor karakteriseren van biopharmaceuticals
  • Ervaring met het valideren van analytische methoden volgens de ICH richtlijnen
  • Ervaring met het schrijven van onderzoeksplannen, rapporten en manuscripten
  • Goed en gestructureerd kunnen presenteren van onderzoekplannen en resultaten binnen en buiten Intravacc
  • Opzetten van interne en externe samenwerkingsverbanden
  • Ervaring met het begeleiden van onderzoeksmedewerkers
  • Ervaring met design of experiments (DoE) is een pré
  • Ervaring met het werken in een BSL-II laboratorium is een pré
  • Ervaring met GMP is een pré
  • Flexibele werkhouding en goed in staat om zowel in teamverband als zelfstandig te werken
  • Goede beheersing van de Nederlandse en Engelse taal in woord en geschrift



assays, biofysisch en immunochemisch technieken, testontwikkeling, vaccin, karakterisering, GMP, biopharmaceuticals, ICH/Q2, BSL-II



Het salaris is, afhankelijk van opleiding en ervaring, maximaal € 4905,85 (BBRA-schaal 11) op basis van een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering. Je wordt aangesteld in tijdelijke dienst voor een periode van 12 maanden en als wetenschappelijk medewerker volgens de indeling in het Functiegebouw Rijk.



Voor meer informatie kun je contact opnemen met dr. B. (Bernard) Metz, afdelingshoofd Analysis, Delivery and Formulation (ADF) (T: 030 7920 485) en dr. M. (Maarten) Danial, wetenschappelijk medewerker (T: 030 7920 481).



Wij ontvangen je sollicitatie (motivatiebrief en CV) bij voorkeur digitaal via uiterlijk op 22 november 2019.


Let op interne en VWNW kandidaten genieten de voorkeur.


Download de vacaturetekst (pdf)


Acquisitie n.a.v. deze vacature wordt niet op prijs gesteld.


Visiting address | Antonie van Leeuwenhoeklaan 9 | 3721 MA | Bilthoven | The Netherlands
Postal Address | P.O. Box 450 | 3720 AL | Bilthoven | The Netherlands
Back To Top